PFE Ticker Curator

• Mixed court ruling: Lilly's Lanham Act claim vs Empower dismissed procedurally, but state claims on compounded tirzepatide legality advance
• FDA...

Three drugmakers announced refunds to 340B covered entities for overcharges on certain medications purchased 2024-2026, while one reveals NDC changes.

• Biotech M&A reaches $84B in Q1 2026, up from $44.4B last year – strongest start since 2019
• Pfizer among big pharma peers facing blockbuster drug...

Earnings Outlook

• 🔥 Q1 Expectations: Wall Street expects Pfizer Q1 earnings of $0.74 per share, a 19.6% year-over-year decline, on $13.82...

Wall Street expects a year-over-year decline in Pfizer's Q1 earnings on higher revenues ahead of the report.

Pfizer's analyst call focuses on why Metsera is a strong strategic fit and shares insights into its assets.

Is a dividend cut coming for PFE?

• Payout ratio still over 100% as 2025 per-share profits declined
• Significant impairment charges eroded earnings
• Company paid out more in dividends than profits

Shareholders face elevated risks.

Pfizer and BioNTech announced topline data from an open-label Phase 3 trial cohort enrolling 100 participants—50 adults aged 65+ and 50 aged 18-64.

• Oncology outreach during Cancer Prevention Month lifts PFE 1.92% to $26.78, emphasizing early screenings
• Modest rebound from near $26.51 support...

Key expert insights from Kaida BioPharma's Dr. Vnook on policy pressures:

• PBM reforms, transparency, value-based contracts can cut patient costs...

Pfizer recalibrates post-COVID BioNTech partnership, which scaled from 2018 flu vaccines to global mRNA success without full ownership.

• Strategic...

Growing accumulation trend in PFE: Institutions own 68.36% and continue adding shares.

• World Investment Advisors +11.2% (added 40,239 shares, now...

Key win for PFE: Settlements with Dexcel, Hikma, and Cipla extend U.S. Vyndamax patent expiry to June 1, 2031, averting sharp revenue drop expected...

Key settlements with Dexcel, Hikma, and Cipla extend tafamidis (Vyndamax) exclusivity to June 1, 2031.

• Revenue protection: Avoids post-2028 U.S....

Key Wall Street estimates for Pfizer's Q1:

• EPS: $0.74, down 19.6% YoY; consensus cut 1.7% in last 30 days
• Revenue: $13.82B, up 0.8% YoY
• Product...

Eli Lilly crushed Q1 with EPS $8.55 (beat +21%) and $19.8B revenue (+12% surprise), topping estimates 4/4 quarters.

Pfizer expectations lag: Q1 EPS...

• Lilly's jab: CEO Ricks claims Pfizer's dual amylin/calcitonin agonists (DACRA) miss their selective amylin bias, risking GI side effects.
• Pfizer's...

Elrexfio (elranatamab) improves PFS in relapsed/refractory multiple myeloma patients who've had at least one prior treatment, per Phase 3 MagnetisMM-5 results – bolstering Pfizer's oncology pipeline.

Oncology Pipeline Wins

• 🔥 Elrexfio Phase 3 Success: Pfizer's Elrexfio met its primary Phase 3 PFS endpoint in the MagnetisMM-5 trial for...

Pfizer's 6.55% dividend yield draws income investors despite declining COVID demand and patent losses:

• Stable cash flow and dividend growth history...